About: Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: To outline an outpatient-based treatment for children with relapsed solid tumors, who already have been extensively pretreated, we defined a 4-drug protocol named COMBAT (combined oral maintenance biodifferentiating and antiangiogenic therapy). Using this protocol, we performed a pilot study to determine its feasibility in children with relapsed and/or high-risk pediatric solid tumors. Patients and Methods: 22 children received the COMBAT protocol. Treatment consisted of daily celecoxib administration along with daily 13-cisretinoic acid (2 weeks on / 2 weeks off) and cycles of metronomic temozolomide (90 mg/m2 for 42 days) and low-dose etoposide (21 days). The treatment was scheduledfor a period of 1 year. Background: To outline an outpatient-based treatment for children with relapsed solid tumors, who already have been extensively pretreated, we defined a 4-drug protocol named COMBAT (combined oral maintenance biodifferentiating and antiangiogenic therapy). Using this protocol, we performed a pilot study to determine its feasibility in children with relapsed and/or high-risk pediatric solid tumors. Patients and Methods: 22 children received the COMBAT protocol. Treatment consisted of daily celecoxib administration along with daily 13-cisretinoic acid (2 weeks on / 2 weeks off) and cycles of metronomic temozolomide (90 mg/m2 for 42 days) and low-dose etoposide (21 days). The treatment was scheduledfor a period of 1 year. (en) Studie popisuje toxicitu, toleranci a klinický efekt experimentální metronomické terapie v pilotní studii u dětí s vysoce rizikovými relabujícími a rekurentními solidními nádory. (cs)
Title	Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study (en) Kombinovaná perorální biodiferenciační, metronomická antiangiogenní terapie u dětí s resistentními, relabujícími solidními nádory. Pilotní studie (cs)
skos:prefLabel	Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study (en) Kombinovaná perorální biodiferenciační, metronomická antiangiogenní terapie u dětí s resistentními, relabujícími solidními nádory. Pilotní studie (cs)
skos:notation	RIV/65269705:_____/06:#0000065!RIV08-MZ0-65269705
http://linked.open.../vavai/riv/strany	308-313
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(NR8448)
http://linked.open...iv/cisloPeriodika	5
http://linked.open...vai/riv/dodaniDat	2008
http://linked.open...aciTvurceVysledku	Pavelka, Zdeněk Štěrba, Jaroslav Mazánek, P. Valík, Dalibor Múdry, Peter Bajčiová, Viera Kepák, Tomáš
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Brno / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	469098
http://linked.open...ai/riv/idVysledku	RIV/65269705:_____/06:#0000065
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Angiogenic; treatment; clinical trial; child (en)
http://linked.open.../riv/klicoveSlovo	clinical trial treatment Angiogenic child - threat - divorce - domestic violence - abandonment - adoption
http://linked.open...odStatuVydavatele	DE - Spolková republika Německo
http://linked.open...ontrolniKodProRIV	[418B7B25D880]
http://linked.open...i/riv/nazevZdroje	Onkologie
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	9 (xsd:int)
http://linked.open...cetTvurcuVysledku	9 (xsd:int)
http://linked.open...vavai/riv/projekt	Characterization of leukemia cell gene expression using DNA microarrays and its utilization for molecular diagnostics and therapy response prediction
http://linked.open...UplatneniVysledku	2006
http://linked.open...v/svazekPeriodika	29
http://linked.open...iv/tvurceVysledku	Múdry, Peter Valík, Dalibor Zitterbart, Karel Štěrba, Jaroslav Pavelka, Zdeněk Bajčiová, Viera Kepák, Tomáš Mazánek, Pavel Kadlecová, Věra
issn	0378-584X
number of pages	6 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Sigle-Center Pilot Study

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software